Alder BioPharmaceuticals® to Present at Two Upcoming November Investor Conferences
BOTHELL, Wash., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Bob Azelby, Alder’s president and chief executive officer, at each of the following upcoming healthcare conferences:
-- Credit Suisse 27th Annual Healthcare Conference at 4:00 p.m. MT on Wednesday, November 14, 2018 in Scottsdale, AZ. -- Piper Jaffray 30th Annual Healthcare Conference at 12:00 p.m. ET on Wednesday, November 28, 2018 in New York, NY.
A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for at least 30 days after each live event concludes.
-- Credit Suisse Link: https://cc.talkpoint.com/cred001/111218a_as/?entity=66_N86C10E -- Piper Jaffray Link: https://event.webcasts.com/starthere.jsp?ei=1220175&tp_key=c6ea843e53
About Alder BioPharmaceuticals, Inc.Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contact: Michael SchaffzinStern Investor Relations, Inc.212.362.1200 email@example.com